Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.

Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial

Sesmilo, Gemma, Biller, Beverly M.K., Llevadot, Joan, Hayden, Douglas, Hanson, Greta, Rifai, Nader, Klibanski, Anne · 2000 · Annals of Internal Medicine

Abstract

BACKGROUND: Growth hormone-deficient adults have increased cardiovascular mortality. Growth hormone replacement may affect cardiovascular risk. Inflammation plays an important role in atherosclerosis, and inflammatory markers are predictive of cardiovascular events. OBJECTIVE: To investigate the effect of growth hormone replacement on inflammatory and other cardiovascular risk factors. DESIGN: Randomized, single-blind, placebo-controlled trial. PATIENTS: 40 men with adult-onset growth hormone deficiency. INTERVENTION: Growth hormone or placebo given for 18 months at a dose adjusted for normal serum insulin-like growth factor I level. MEASUREMENTS: Anthropometric, hemoglobin A1c, and central fat values were assessed every 6 months. Levels of glucose, insulin, insulin-like growth factor I, and lipids were measured at 1, 3, 6, 12, and 18 months. C-reactive protein, serum amyloid polypeptide A, inteleukin-6, and lipoprotein(a) levels were determined at baseline and 6 and 18 months. RESULTS: C-reactive protein and inteleukin-6 levels decreased in growth hormone recipients compared with placebo recipients (differences between groups, -1.9 +/- 0.6 mg/L [P = 0.0027] and -1.3 +/- 0.5 ng/L [P = 0.013], respectively). Changes in serum amyloid polypeptide A levels between groups did not reach statistical significance (difference between groups, -2.4 +/- 1.2 mg/L; P = 0.056). Serum cholesterol levels, low-density lipoprotein cholesterol levels, and ratios of total cholesterol to high-density lipoprotein cholesterol decreased in growth hormone recipients in the first 3 months compared with placebo recipients (differences between groups, -0.86 +/- 0.17 mmol/L [-33.2 +/- 6.6 mg/dL] [P < 0.001], -0.63 +/- 0.20 mmol/L [-24.5 +/- 5.9 mg/dL] [P < 0.001], and -0.56 +/- 0.26 [P = 0.040], respectively), but the decrease was not maintained from month 6 to month 18. Lipoprotein(a) levels increased (difference between groups, 22.0 +/- 8.0 mg/L; P = 0.0096). Short-term increases occurred in glucose levels, insulin levels, and insulin-to-glucose ratios (differences between groups, 0.54 +/- 0.16 mmol/L [9.6 +/- 2.8 mg/dL] [P = 0.0018], 37.9 +/- 9.6 pmol/L [P < 0.001], and 6.0 +/- 1.8 [P = 0.0025], respectively), but only the increase in glucose level was maintained over the long term (difference between groups, 0.56 +/- 0.17 mmol/L [10.0 +/- 3.1 mg/dL]; P = 0.0026). Hemoglobin A1c values did not change. Truncal fat-to-total fat ratios decreased (difference between groups, -0.018 +/- 0.007; P = 0.0087). CONCLUSIONS: Long-term growth hormone replacement in men reduces levels of inflammatory cardiovascular risk markers, decreases central fat, and increases lipoprotein(a) and glucose levels without affecting lipid levels.

Overview

Integrity signals

Registry

Crossref · 10.7326/0003-4819-133-2-200007180-00010

Cites

68 of 68 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 68 references

Research works printed but not linked: 13

  1. Pfeifer M, 1999, J Clin Endocrinol Metab, 84, 453
  2. De Boer H, 1992, J Clin Endocrinol Metab, 75, 833
  3. Weaver JU, 1995, J Clin Endocrinol Metab, 80, 153
  4. Cuneo RC, 1998, J Clin Endocrinol Metab, 83, 107
  5. Bengtsson BA, 1993, J Clin Endocrinol Metab, 76, 309
  6. Beshyah SA, 1995, J Clin Endocrinol Metab, 80, 356
  7. Hwu CM, 1997, J Clin Endocrinol Metab, 82, 3285
  8. Borson-Chazot F, 1999, J Clin Endocrinol Metab, 84, 1329
  9. Baum HB, 1998, J Clin Endocrinol Metab, 83, 3184
  10. Hadigan C, 1999, J Clin Endocrinol Metab, 84, 1932
  11. Serri O, 1999, J Clin Endocrinol Metab, 84, 58
  12. 10.1001/jama.1993.03500230097036 · DOI · Paper page
  13. Attanasio AF, 1997, J Clin Endocrinol Metab, 82, 82

Cited by

See all 257

Metadata

Authors
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A.
Affiliations
Brigham and Women's Hospital (US)
Corresponding author
Sesmilo, Gemma
Venue
Annals of Internal Medicine
Published
2000-07-18
Volume
133
Issue
2
Pages
111-122
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2042102742
Cited by
257
References
68
Citations by year
2025: 2 · 2024: 3 · 2023: 2 · 2022: 7 · 2021: 3 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 7 · 2016: 8 · 2015: 10 · 2014: 9 · 2013: 10 · 2012: 13
FWCI
9.71
Type
journal article
Language
en
Open access
closed
Licence
www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
Locations
  • Annals of Internal Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1f32dk008783-01a1)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK-08783)
  • National Center for Research Resources (M01RR001066, RR-1066)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Growth Hormone and Insulin-like Growth Factors
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Keywords
growth hormone replacement therapy, adult-onset growth hormone deficiency, cardiovascular risk factors, inflammation, C-reactive protein, interleukin-6, lipoprotein(a), insulin-like growth factor I, lipid profile, LDL cholesterol, cardiovascular mortality, men, atherosclerosis, central fat, insulin resistance, HbA1c
MeSH terms
Adipose Tissue, Adult, Serum Amyloid A Protein, Analysis of Variance, Anthropometry, Blood Glucose, C-Reactive Protein, Cardiovascular Diseases, Humans, Inflammation, Insulin-Like Growth Factor I, Lipids, Male, Middle Aged, Placebos, Risk Factors, Interleukin-6, Single-Blind Method, Human Growth Hormone, Hormone Replacement Therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial. https://app.cochat.ai/papers/10.7326/0003-4819-133-2-200007180-00010
The paper
Sesmilo, G., Biller, B. M. K., Llevadot, J., Hayden, D., Hanson, G., Rifai, N., & Klibanski, A. (2000). Effects of Growth Hormone Administration on Inflammatory and Other Cardiovascular Risk Markers in Men with Growth Hormone Deficiency: A Randomized, Controlled Clinical Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-133-2-200007180-00010

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.